3D-Printed Drugs for Children—Are We Ready Yet?
- 1.1k Downloads
The first medicine manufactured by three-dimensional (3D) printing was recently approved by the Food and Drug Administration (FDA). The advantages of printing as a manufacturing route enabling more flexibility regarding the dose, and enlarging individual treatment options, have been demonstrated. There is a particular need for flexible drug delivery solutions when it comes to children. Printing as a new pharmaceutical manufacturing technology brings manufacturing closer to the patient and can easily be adjusted to the required dosing scheme, offering more flexibility for treatments. Printing of medicine may therefore become the manufacturing route of choice to provide tailored and potentially on-demand treatments for patients with individual needs. This paper intends to summarize and discuss the state of the art, the crucial aspects which should be taken into account, and the still-open questions, in order to make 3D printing a suitable manufacturing route for pediatric drugs.
KEY WORDS3D printing children drug delivery pediatrics
We would like to thank the Finnish Cultural Foundation (00161140) and the Academy of Finland ( 297293) for their support.
- 1.United States Food and Drug Administration. Paving the way for personalized medicine. 2013.Google Scholar
- 2.Norman J, et al.. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Adv Drug Delivery Rev. 2016. In press. doi: 10.1016/j.addr.2016.03.001.
- 7.Aprecia Pharmaceuticals. 3D Printing/ZipDose technology. 2016. Available at: https://www.aprecia.com/zipdose-platform/3d-printing.php
- 8.European parliament. Open innovation in industry, including 3D printing. 2015. Available at: http://www.europarl.europa.eu/RegData/etudes/STUD/2015/563445/IPOL_STU(2015)563445_EN.pdf.
- 9.United States Food and Drug Administration. Medical applications of 3D printing. 2016.Google Scholar
- 21.Stoltenberg I, Winzenburg G, Breitkreutz J. Solid oral dosage forms for children—formulations, excipients and acceptance issues. J Appl Ther Res. 2010;7(4):141–6.Google Scholar
- 26.Sanderson K. 3D printing: the future of manufacturing medicine? Pharm J. 2015;294(7865):598–600.Google Scholar
- 27.Preis M, Sandler N. Printing technologies and tailored dosing. Hospital Pharmacy Europe. http://www.hospitalhealthcare.com. 2016.
- 31.U.S. Department of Health and Human Services. Technical considerations for additive manufactured devices—draft guidance for industry and food and drug administration staff. 2016.Google Scholar
- 32.Khairuzzaman A. Before you click “print”: regulatory considerations for 3D-printed drug products. United States Food and Drug Administration. Proceedings of the AAPS Annual Meeting. 2016, Denver.Google Scholar
- 33.Christensen A. Pre-printing considerations. FDA Additive Manufacturing Workshop. 2014.Google Scholar